Reducing Postoperative Opioids in Pediatric Orthopaedics: An Updated Tiered Prescription Guideline with a "Tier 0".

Mikaela H Sullivan, Courtney E Baker, Daniel S Ubl, Elizabeth B Habermann, A Noelle Larson, Todd A Milbrandt
{"title":"Reducing Postoperative Opioids in Pediatric Orthopaedics: An Updated Tiered Prescription Guideline with a \"Tier 0\".","authors":"Mikaela H Sullivan, Courtney E Baker, Daniel S Ubl, Elizabeth B Habermann, A Noelle Larson, Todd A Milbrandt","doi":"10.1016/j.jposna.2024.100124","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There is growing data on strategies to reduce opioid prescriptions in pediatric orthopaedics. Our institution implemented tiered guidelines for opioid discharge prescriptions in 2018 to standardize prescribing patterns across our entire pediatric orthopaedics practice. In 2022, we updated the tiered system with a goal to further minimize the quantity of opioids prescribed and eliminate opioids altogether for certain procedures. The aim of this project was to evaluate the effects of the updated tiered guidelines for discharge opioid prescribing following common pediatric orthopaedic procedures.</p><p><strong>Methods: </strong>A quality improvement project was conducted at a single academic institution. Guidelines for discharge opioid prescriptions were updated in January 2022 and established 5 tiers of increasing invasiveness for 28 procedures. The updated guidelines included a \"Tier 0\" which provided no opioids, reorganized surgical tiers based on prior data, and decreased the doses recommended for tiers. Opioid prescriptions were reported as oral morphine equivalents (OMEs). Univariate tests were performed to assess statistically significant differences before and after implementation of updated guideline eras, comparing 2020-2021 and 2022.</p><p><strong>Results: </strong>Overall, 747 patients (2020-2021, <i>n</i> ​= ​500; 2022, <i>n</i> ​= ​247) were included. The proportion of patients receiving discharge opioid prescriptions decreased from 89.8% to 80.6% (<i>P</i> ​< ​0.05), between 2020 and 2021 and 2022. This resulted in decreased overall OME prescribed (median 75 vs 45, <i>P</i> ​< ​0.05) and OME prescribed in those >10 years (135 vs 113, <i>P</i> ​< ​0.05) while 30-day refill rates (9.4% vs 6.1%), and OME per kilogram in those <11 years of age (median 0.9 vs 0.8) remained unchanged (both <i>P</i> ​> ​0.05). Discharge prescriptions falling within overall guidelines increased after guideline implementation (83.3% vs 85.4%), though this was not statistically significant and guideline adherence was low among Tier 0 ​at 31%.</p><p><strong>Conclusions: </strong>Including \"Tier 0\" of procedures receiving no opioid prescriptions, reorganizing procedures within tiers, and decreasing the recommended doses to an already strict tiered guideline for discharge opioid prescriptions significantly decreased the quantity of opioids prescribed. We noted continued excellent overall adherence and, importantly, no overall increase in refills, with areas for improvement in Tier 0. Quality improvement projects can continue to reduce the amount of opioids prescribed following pediatric orthopaedic procedures.</p><p><strong>Key concepts: </strong>(1)Updated tiered guidelines, including a \"Tier 0\" for discharge opioid prescriptions following pediatric orthopaedic procedures were effective in reducing the quantity of opioids provided at discharge.(2)A continued high adherence rate was observed with the updated guidelines, though areas for improvement include adherence to no opioids in Tier 0.(3)Refill rates remained similar after implementation of the updated guidelines.(4)The study results suggest opportunities for continued improvement projects to reduce the number of unnecessary opioids prescribed to pediatric orthopaedic patients.</p><p><strong>Level of evidence: </strong>III.</p>","PeriodicalId":520850,"journal":{"name":"Journal of the Pediatric Orthopaedic Society of North America","volume":"9 ","pages":"100124"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12088344/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Pediatric Orthopaedic Society of North America","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.jposna.2024.100124","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: There is growing data on strategies to reduce opioid prescriptions in pediatric orthopaedics. Our institution implemented tiered guidelines for opioid discharge prescriptions in 2018 to standardize prescribing patterns across our entire pediatric orthopaedics practice. In 2022, we updated the tiered system with a goal to further minimize the quantity of opioids prescribed and eliminate opioids altogether for certain procedures. The aim of this project was to evaluate the effects of the updated tiered guidelines for discharge opioid prescribing following common pediatric orthopaedic procedures.

Methods: A quality improvement project was conducted at a single academic institution. Guidelines for discharge opioid prescriptions were updated in January 2022 and established 5 tiers of increasing invasiveness for 28 procedures. The updated guidelines included a "Tier 0" which provided no opioids, reorganized surgical tiers based on prior data, and decreased the doses recommended for tiers. Opioid prescriptions were reported as oral morphine equivalents (OMEs). Univariate tests were performed to assess statistically significant differences before and after implementation of updated guideline eras, comparing 2020-2021 and 2022.

Results: Overall, 747 patients (2020-2021, n ​= ​500; 2022, n ​= ​247) were included. The proportion of patients receiving discharge opioid prescriptions decreased from 89.8% to 80.6% (P ​< ​0.05), between 2020 and 2021 and 2022. This resulted in decreased overall OME prescribed (median 75 vs 45, P ​< ​0.05) and OME prescribed in those >10 years (135 vs 113, P ​< ​0.05) while 30-day refill rates (9.4% vs 6.1%), and OME per kilogram in those <11 years of age (median 0.9 vs 0.8) remained unchanged (both P ​> ​0.05). Discharge prescriptions falling within overall guidelines increased after guideline implementation (83.3% vs 85.4%), though this was not statistically significant and guideline adherence was low among Tier 0 ​at 31%.

Conclusions: Including "Tier 0" of procedures receiving no opioid prescriptions, reorganizing procedures within tiers, and decreasing the recommended doses to an already strict tiered guideline for discharge opioid prescriptions significantly decreased the quantity of opioids prescribed. We noted continued excellent overall adherence and, importantly, no overall increase in refills, with areas for improvement in Tier 0. Quality improvement projects can continue to reduce the amount of opioids prescribed following pediatric orthopaedic procedures.

Key concepts: (1)Updated tiered guidelines, including a "Tier 0" for discharge opioid prescriptions following pediatric orthopaedic procedures were effective in reducing the quantity of opioids provided at discharge.(2)A continued high adherence rate was observed with the updated guidelines, though areas for improvement include adherence to no opioids in Tier 0.(3)Refill rates remained similar after implementation of the updated guidelines.(4)The study results suggest opportunities for continued improvement projects to reduce the number of unnecessary opioids prescribed to pediatric orthopaedic patients.

Level of evidence: III.

减少小儿骨科术后阿片类药物:更新的“0级”分级处方指南
背景:有越来越多的数据策略,以减少阿片类药物处方在儿科骨科。我们机构在2018年实施了阿片类药物出院处方分级指南,以规范我们整个儿科骨科实践的处方模式。2022年,我们更新了分级系统,目标是进一步减少处方阿片类药物的数量,并在某些程序中完全消除阿片类药物。该项目的目的是评估更新后的分级指南对普通儿科骨科手术后阿片类药物出院处方的影响。方法:在某学术机构进行质量改进项目。阿片类药物出院处方指南于2022年1月更新,并为28种程序建立了5级侵入性增加。更新后的指南包括不提供阿片类药物的“0级”,根据先前的数据重组了手术级别,并减少了推荐级别的剂量。阿片类药物处方被报道为口服吗啡当量(OMEs)。采用单变量检验,比较2020-2021年和2022年新版指南实施前后的统计学显著差异。结果:总体而言,747例患者(2020-2021,n = 500;包括2022,n = 247)。出院时接受阿片类药物处方的患者比例从89.8%下降到80.6% (P < 0.05) (P < 135 vs . 113)。在指南实施后,符合总体指南的出院处方增加了(83.3%对85.4%),尽管这没有统计学意义,并且0级患者的指南依从性较低,为31%。结论:纳入没有阿片类药物处方的“第0层”程序,重新组织分层程序,并将推荐剂量降低到已经严格的阿片类药物出院指南中,可显着减少阿片类药物的处方数量。我们注意到整体依从性持续良好,重要的是,在第0级有改进的领域,没有总体增加。质量改进项目可以继续减少小儿骨科手术后开具的阿片类药物的数量。关键概念:(1)更新的分级指南,包括儿科骨科手术后出院阿片类药物处方的“0级”,有效地减少了出院时提供的阿片类药物的数量。(2)使用更新的指南观察到持续的高依从率。尽管需要改进的领域包括0级无阿片类药物的依从性。(3)更新指南实施后,再填充率保持相似。(4)研究结果表明,有机会继续改进项目,减少儿科骨科患者不必要的阿片类药物处方数量。证据水平:III。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信